Reported by IT Chosun / May 18, 2023
HoneyNaps announced on May 18th that they have signed a Memorandum of Understanding (MOU) with Whan In Pharm. for the development of digital therapeutic solutions for insomnia.
Digital therapeutics refer to Software as a Medical Devices (SaMD) that are intended for the prevention, management, or treatment of diseases, going beyond disease diagnosis, patient monitoring, and decision support. In particular, digital therapeutics for insomnia are based on cognitive behavioral therapy and can be used in the medical field as alternatives or adjuncts to medication.
HoneyNaps and Whan In Pharm. will collaborate based on mutual trust through this business agreement to drive the development of digital therapeutics for insomnia. They also plan to establish a business model that can be integrated with the pharmaceutical industry through the exchange of related information.
HoneyNaps, in collaboration with Professor Seokhoon Jeong's team from the Department of Psychiatry at Seoul Asan Hospital, has completed a clinical trial on 'Sleep Index-based Cognitive Behavioral Therapy for Insomnia (CBT-I) Digital Therapeutic Device.' HoneyNaps has expanded its expertise by integrating diagnostic technologies for sleep disorders with treatment capabilities, and possesses a solution pipeline in this field.